Previous 10 | Next 10 |
2023-07-14 11:54:56 ET Axonics, ( NASDAQ: AXNX ) and Shockwave Medical ( NASDAQ: SWAV ) moved in opposite directions Friday after the Centers for Medicare & Medicaid Services (CMS) proposed changes to 2024 Medicare reimbursement rates for hospital outpatient department...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2023 financial results after the close of trading on Thursday, July 27. Axonics will host a co...
2023-05-12 08:48:10 ET Summary AXNX reported impressive 1Q23 earnings with revenue of $70.7 million, representing a remarkable 46% year-on-year growth. The success of Axonics' F15 and Bulkamid products played a significant role in driving their strong performance. AXNX raised ...
2023-05-10 09:41:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Small Cap Fund® (the Fund) was up 9.44% (Institutional Shares) in the first...
2023-05-09 13:25:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Discovery Fund® (the Fund) was up 11.20% compared...
2023-05-04 06:22:39 ET Summary Axonics is under pressure after Q1 results came in solid but guidance didn't increase as much as hoped. The company has 2 solid products and the medical technology space has performed well recently. AXNX is a volatile small cap but the recent wea...
2023-05-01 21:36:06 ET Axonics, Inc. (AXNX) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Chris Pasquale - Nephron...
2023-05-01 17:08:29 ET Axonics Modulation Technologies press release ( NASDAQ: AXNX ): Q1 GAAP EPS of -$0.19. Revenue of $70.7M (+46.0% Y/Y). Gross margin was 74.3% in 1Q23 compared to 68.7% in the prior year period. Operating expenses were $66.9 million in 1Q23 an...
Generated quarterly revenue of $70.7 million, an increase of 46% year over year Fiscal year 2023 revenue guidance increased to $348 million Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment o...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following upcoming investor conferences: Event: BofA Securities Healthcare Conference ...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...